HOME >> MEDICINE >> NEWS
Doctors focus on pupil size for safety of laser vision correction

Exactly how a persons eyes respond to low levels of light is even more crucial than doctors have thought in deciding who is and who isnt a good candidate to have laser vision correction surgery, according to results announced today at the annual meeting of the Association for Research in Vision and Ophthalmology in Ft. Lauderdale. The findings should help doctors choose patients who are likely to fare well with the surgery, and to forego recommending treatment for others.

In the earliest days of laser vision correction, some patients complained of worsened night vision after the surgery some reported significant glare from light sources such as headlights at night, while others saw halos around bright lights. Occasionally, though much more rarely, patients undergoing the procedure still report such side effects.

Ophthalmologist Scott MacRae, M.D., professor of Ophthalmology and Visual Science at the University of Rochester Medical Center, recently studied the role of a patients pupil size in determining a patients outcome from the surgery. In a study of 340 patients, he found that generally the larger a patients pupils, the more likely that person is to have a problem with laser vision correction. MacRae also discussed the results at the recent annual meeting of the Association for Cataract and Refractive Surgery in San Francisco.

This is not a problem for most people, says MacRae, but as the procedure becomes more common, we have to make sure that we remain vigilant to protect and enhance peoples eyesight.

MacRae is part of a team that has used a technology known as adaptive optics to discover dozens of previously unknown subtle imperfections in the eye, and he has found that those imperfections loom more important as the pupil size gets larger. He reports that if a surgeon treats a large enough swath of the eye for such patients, those imperfections are minimized. His study shows that its essential that doctors trea
'"/>

Contact: Tom Rickey
trickey@admin.rochester.edu
585-275-7954
University of Rochester Medical Center
6-May-2003


Page: 1 2 3

Related medicine news :

1. Doctors need to prepare for blood shortages now
2. Doctors must consider potentially inappropriate medications when treating elderly
3. Doctors transplant ovary to womans arm to preserve fertility
4. Doctors can improve colorectal cancer screening rates
5. Doctors miss chances to provide diet, exercise counseling to patients at risk of heart disease
6. Doctors and patients call on politicians to save lives of cancer patients
7. Doctors dont agree on diagnosis of uterine cancer
8. Doctors at Northwestern Memorial are studying next generation surgery for back pain sufferers
9. U-M study: Doctors more likely to prescribe pricey new blood pressure drugs
10. Doctors over-estimate survival of terminally ill patients
11. Doctors are often strongly affected by patient deaths

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Doctors focus pupil size for safety laser vision correction

(Date:5/21/2013)... Colo. (May 21, 2013) Research into genetic features ... University of Colorado School of Medicine may lead to ... a paper published online by JAMA . , ... predict survival in some cases of pulmonary fibrosis, a ... years. As a result of the study, researchers may ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 While ... is synonymous with comprehensive travel guides. Brunswick Plantation & ... golf packages that include access to 27 holes of ... golf courses in North Carolina, knowing the Top ... and Lodges takes away the overwhelming task of selecting ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
(Date:5/21/2013)... as 35 percent of Mexican young adults may have ... Illinois scientist who conducted a study at the Universidad ... inherited genetic risk factors from both parents were already ... waist than those who hadn,t. They also had slightly ... of I professor of food science and human nutrition. ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Genetic risk for obesity found in many Mexican young adults 2
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: